Company’s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflowCERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer care’s persistent challenges: NCCN compliance by the medical com ...